Former OpenAI science lead Kevin Weil has launched Warp Sciences, an AI biotech startup that automates laboratory wet-lab operations for drug discovery. The company emerged from secrecy with $215 million in funding at an $865 million valuation, according to an announcement by Weil. The investment round was led by Lightspeed, with participation from IVP, Premji Invest, and Lux Capital.
Warp Sciences uses human chemists wearing cameras and sensor gloves to demonstrate physical tasks, effectively training robotic systems to synthesize and test molecular compounds autonomously. By automating these repetitive physical processes, the platform enables physical labs to run continuously around the clock, significantly speeding up testing cycles for new medical therapies.
The startup aims to reshore labor-intensive chemical synthesis work that Western biotechnology firms historically outsourced to overseas contract development and manufacturing organizations. By building automated physical infrastructure domestically, Warp Sciences seeks to protect early-stage pharmaceutical supply chains from geopolitical disruptions and foreign trade dependencies.
Why it matters
Biotech founders can significantly compress drug discovery timelines by deploying continuous autonomous physical lab automation.
Venture investors continue backing physical AI applications that combine robotics with specialized domain foundation models.
US drug developers gain supply-chain resilience by replacing offshore chemical synthesis contractors with automated onshore labs.
Source: techcrunch.com



